Sanofi stock in focus as Insmed takeover talks emerge
Published on 11/21/2026 at 12:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline strategy moves into focus
- Sanofi is weighing a potential acquisition of US respiratory-drug maker Insmed.
- The review comes under CEO Belen Garijo as Sanofi seeks to strengthen its future medicines pipeline.
- Bloomberg reported that Sanofi is working with advisers, while the potential transaction remains under consideration.
Sanofi is considering an acquisition of US respiratory-drug maker Insmed, Bloomberg reported on Friday, November 20, 2026. The French pharmaceutical group is working with advisers as it assesses a potential transaction, according to people familiar with the matter.
The move would give Sanofi access to Insmed's respiratory portfolio and development pipeline. The report places the review under CEO Belen Garijo, who is seeking to reinforce the group's medicines pipeline as investors look beyond Dupixent's current growth.
Insmed review raises strategic stakes
Insmed focuses on respiratory diseases and has a market value of about 32 billion US dollars, Bloomberg reported. The potential deal would be one of the largest pharmaceutical takeovers in years, although the companies had not announced an agreement by Friday.
The report also highlighted valuation pressure on Sanofi. Bloomberg said the shares traded at nine times estimated earnings, below the average multiple of 17.3 for the world's 10 largest pharmaceutical companies by sales. That comparison frames the possible acquisition as a strategic move with significant financial and execution considerations.
Bloomberg reported the takeover discussions and the involvement of advisers.
Sanofi stock traded at 84.60 euros on Lang & Schwarz at 12:28 CET on Saturday, November 21, 2026, 0.31 percent below the Xetra close of Friday, November 20, at 84.86 euros.
Sanofi market details
- Company: Sanofi S.A.
- ISIN: FR0000120578
- Xetra close: 84.86 euros on Friday, November 20, 2026
- Lang & Schwarz: 84.60 euros at 12:28 CET on Saturday, November 21, 2026
The French market backdrop is covered in Current market reports.
More news and analyses on Sanofi stock.
